title: Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts.
abstract: OBJECTIVE
  The reconstruction of the RVOT in congenital heart disease often requires the implantation of a valved conduit. Although allografts are considered the conduit of choice their availability is limited and therefore xenografts are implanted as well. We compared the long-term durability of both grafts in the RVOT over a 25-year period.
  
  
  METHODS
  Between January 1974 and August 1999, 505 patients (median age 4.0 years, range 2 days-31 years; median weight 14.5 kg, range 2.2-76.6 kg; median body length 103 cm, range 48-183 cm) with congenital malformations (PA 25.3%, TOF 14.5%, TOF+PA 2.4%, DORV 4.2%, TGA+PS 8.7%, TAC 24.8%, and other 20.2%) received their first valved conduit (174 xenografts: median diameter 14 mm, range 8-27 mm; 331 allografts: median diameter 19 mm, range 8-30 mm).
  
  
  RESULTS
  Follow-up is 3017 patient-years. The 10-year survival-probability for all patients. was 66% with a mean reoperation-free interval for conduit-exchange of 13.3 years (mean reoperation-free interval for allografts, 16.0 years; mean reoperation-free interval for xenograft, 10.3 years). One hundred and thirteen patients underwent a conduit-exchange, mostly due to conduit stenosis. Fourteen patients had a second exchange and three patients a third exchange. For patients with conduit diameters <18 mm (n=235: allograft n=116, xenograft n=119; median age 9 months, range 0-27.3 years), the mean reoperation-free interval was 11.2 years (mean interval allograft, 13.1 years; mean interval xenograft, 8.6 years, P=0.03). For conduit diameters >/=18 mm (n=270: allograft n=215, xenograft n=55, median age 7.4 years, range 0-34.3 years) the mean interval from freedom of conduit exchange was 15.1 years (for allografts 14.1 years, for xenografts 12.5 years, P<0.01). Comparing xenografts to allografts, we found no difference in patient survival probability (P=0.62). There was no significant difference between antibiotic (n=198) preserved vs. cryopreserved (n=133) allografts (P=0.06). Blood group compatibility of allografts to recipients had no significant influence on allograft function (P=0.42). The donors allograft origin, whether aortic or pulmonary valve, had also no significant influence on allograft long-term function (P=0.15).
  
  
  CONCLUSIONS
  For the reconstruction of the right ventricular outflow tract (RVOT) allografts show significantly better long-term durability than xenografts regardless of the age at implantation and the diameter.
authors.affiliation: German Heart Center Munich, Department of Cardiac Surgery, Lazarettstrasse 36, D-80636, München, Germany. homann@dhm.mhn.de
authors.forename: M
authors.initials: M
authors.lastname: Homann
authors.forename: J C
authors.initials: JC
authors.lastname: Haehnel
authors.forename: N
authors.initials: N
authors.lastname: Mendler
authors.forename: S U
authors.initials: SU
authors.lastname: Paek
authors.forename: K
authors.initials: K
authors.lastname: Holper
authors.forename: H
authors.initials: H
authors.lastname: Meisner
authors.forename: R
authors.initials: R
authors.lastname: Lange
mesh_terms: D000293:Adolescent; D000328:Adult; D001705:Bioprosthesis; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006330:Heart Defects, Congenital / Q000175:diagnosis / Q000601:surgery*; D006343:Heart Septal Defects / Q000175:diagnosis / Q000601:surgery; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods* / Q000401:mortality; D006352:Heart Ventricles / Q000002:abnormalities; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011379:Prognosis; D011664:Pulmonary Valve / Q000002:abnormalities* / Q000601:surgery*; D012189:Retrospective Studies; D016019:Survival Analysis; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous